Tenderwize
Wróć do wyszukiwania

Non-exclusive rebate agreement for Aflibercept injectable solution in vial

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 126 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschl. nicht exkl. Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Modells zum WS Aflibercept (ATC-Code nach WHO: S01LA05; ausgen. 114,3 mg/ml) als Injektionsl. in einer Durchstechflasche

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The exact submission process is unclear because the structured data says electronic submission is not allowed, while th...

Demand and purchase volume are explicitly unknown, and no minimum quantity is guaranteed.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial.
  • Open-House participation model: any interested pharmaceutical company may join during the participation period if it meets and accepts the participation conditions.
Pokaż pełne podsumowanie

This is an Open-House supply arrangement for non-exclusive rebate agreements under §130a(8) SGB V for Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial. The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. The notice indicates electronic communication via DTVP, but participation documents must be obtained from the project room after access approval. The contract ends no later than 31.12.2026, and the purchase volume is unknown with no minimum quantity guaranteed.

Ryzyka

The exact submission process is unclear because the structured data says electronic submission is not allowed, while th...

Demand and purchase volume are explicitly unknown, and no minimum quantity is guaranteed.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company or its local representative may participate only if it itself qualifies as a pharmaceutical company for the offered product.
  • No Russia-related connection within the meaning of Article 5k of Regulation (EU) No 833/2014, as amended by Regulation (EU) 2022/576, must be declared using the provided...

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive rebate agreement for Aflibercept injectable solution in vial

Single lot covering non-exclusive rebate agreements for Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial. This is an Open-House model with no exclusivity, no individual negotiations, and unknown demand/volume. Place of performance is Dresden, Germany, with performance also referenced for Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Dec 2025 - Dec 2026

Kategoria

Pharmaceutical products

Termin

Deadline Dec 31, 2026

Szczegóły zamówienia

Data publikacji
11 Nov 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
750728-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3